Royalty Pharma has secured a stake…
Royalty Pharma has secured a stake in another transthyretin-mediated amyloidosis [...]
A phase 2 study of Celldex’s…
A phase 2 study of Celldex’s barzolvolimab in a chronic [...]
A rare disease startup with a…
A rare disease startup with a mission to repurpose proven [...]
For years, as Big Pharma poured…
For years, as Big Pharma poured billions into ADCs, Novartis [...]
Jupiter Neurosciences will pay…
Jupiter Neurosciences will pay $3.3 million upfront to Canada’s PharmAla [...]
Axiom Biosciences intends to…
Axiom Biosciences intends to pursue an IPO on the Hong [...]
A phase 3 trial of Kolon…
A phase 3 trial of Kolon TissueGene’s cell-based gene therapy [...]
Scribe Therapeutics has put its…
Scribe Therapeutics has put its IPO plans down on paper, [...]
Latigo Biotherapeutics is…
Latigo Biotherapeutics is preparing to go public in order to [...]
Geopolitical uncertainty has…
Geopolitical uncertainty has continued to “chill” IPO sentiment among British [...]